Plasma samples from patients in the OPERA trial were examined for CXCL13 at treatment initiation and after 6 months of treatment with either methotrexate plus placebo ( DMARD ) ( n = 37 ) or methotrexate plus adalimumab ( DMARD + ADA ) ( n = 39 ) .